Cell preparation mycoplasma detection method and kit thereof

By using α-mannosidase and 6-chloro-3-indole-a-D-mannosidoside in cell preparations, combined with choma-beanin inhibitors, it is solved that it is difficult to simultaneously detect extracellular and The problem of mycoplasma intracellularity, achieving high sensitivity detection and lower detection limits, provides an assessment of the impact of cell infection.

CN118957017AInactive Publication Date: 2024-11-15GUANGZHOU SHAAI BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202411231430.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art is difficult to detect the extracellular and intracellular mycoplasma content in cell preparations efficiently, affecting cell quality control and microbial safety evaluation.

Method used

The mapping relationship between mycoplasma concentration and absorbance signal was constructed by incubating α-mannosidase and 6-chloro-3-indole-a-D-mannosidosid in a specific pH buffer solution. Combined with the choma-bean inhibitor. , realize simultaneous detection of extracellular and intracellular mycoplasma in cell preparations.

Benefits of technology

Simultaneous detection of extracellular and intracellular mycoplasma content in cell preparations is achieved, lower detection limits and higher detection sensitivity are obtained, and evaluation indicators are provided for cell infection that is affected by the extracellular environment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957017A_ABST
    Figure CN118957017A_ABST
Patent Text Reader

Abstract

The invention provides a method for detecting mycoplasma of a cell preparation. The method comprises the following steps: (1) incubating quantitative cell preparation samples to be detected, quantitative alpha-mannosidase and quantitative 6-chloro-3-indole-a-D-mannoside in a buffer solution with the pH value of 3.5-4.5 at 36-38 DEG C for 15-60 minutes; (2) adding a quantitative swainsonine inhibitor into the reaction system to terminate the reaction when the incubation is finished; and (3) detecting the light absorption signal intensity of the liquid treated in the step (2) at 505-515nm. The invention provides simultaneous detection of extracellular and intracellular mycoplasma contents of a cell preparation for the first time, the extracellular mycoplasma concentration A and the intracellular mycoplasma concentration B are obtained, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is marked as an environmental influence coefficient alpha; the smaller the alpha is, the smaller the influence of the extracellular environment of the cell preparation on the cell infection in the cell preparation is.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cell preparation detection, and in particular to a cell preparation mycoplasma detection method and a kit thereof. Background Art

[0002] The research hotspots in the field of cell therapy are stem cells and immune cells, which must comply with national laws, regulations and administrative regulations. The cell source, production process and clinical application process must be carried out under the premise of compliance. Mycoplasma is a common exogenous contaminant in the cell culture process. Carrying out mycoplasma contamination detection is an important part of the cell quality control microbiological safety evaluation system. Summary of the invention

[0003] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a method for detecting mycoplasma in cell preparations and a kit thereof.

[0004] To achieve the above object, the technical solution adopted by the present invention is: a method for detecting mycoplasma in cell preparations, the detection method comprising the following steps:

[0005] (1) incubating the quantitative cell preparation sample to be tested with quantitative α-mannosidase and quantitative 6-chloro-3-indole-aD-mannoside in a buffer solution with a pH of 3.5 to 4.5 at 36 to 38° C. for 15 to 60 minutes;

[0006] (2) at the end of the incubation, a quantitative swainsonine inhibitor was added to the reaction system to terminate the reaction;

[0007] (3) detecting the absorbance signal intensity of the liquid treated in step (2) at 505 to 515 nm;

[0008] (4) preparing 5 to 8 mycoplasma solutions of different concentrations in the range of 0 to 200 CFU / mL, including a blank solution, and treating the 5 to 8 mycoplasma solutions of different concentrations in accordance with steps (1) to (3) in sequence to obtain a mapping relationship between the mycoplasma solution concentration and the absorbance signal intensity;

[0009] (5) Substituting the absorbance signal intensity of the cell preparation sample to be tested into the mapping relationship obtained in step (4) to calculate the mycoplasma concentration in the cell preparation sample to be tested.

[0010] In the above-mentioned method for detecting mycoplasma in cell preparations, mycoplasma has an inhibitory effect on α-mannosidase. After α-mannosidase hydrolyzes the chromogenic substrate 6-chloro-3-indole-aD-mannoside, the absorbance signal at 505-515nm changes. By constructing a mapping relationship between the mycoplasma content and the absorbance signal, the mycoplasma content in the cell preparation can be detected.

[0011] Preferably, in the step (1), the quantitative cell preparation sample to be tested is centrifuged to collect the supernatant A and the precipitated cells; the precipitated cells are added to a quantitative buffer solution with a pH of 3.5 to 4.5 and suspended and mechanically disrupted to obtain a cell disruption solution B; the supernatant A and the cell disruption solution B are respectively subjected to the treatment and detection of steps (1) to (3) to obtain an absorbance signal intensity A of the supernatant A and an absorbance signal intensity B of the cell disruption solution B; the absorbance signal intensity A and the absorbance signal intensity B are substituted into the mapping relationship obtained in step (4) to obtain a mycoplasma concentration A in the supernatant A and a mycoplasma concentration B in the cell disruption solution B, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α.

[0012] In the above-mentioned cell preparation mycoplasma detection method, the cell preparation to be tested is centrifuged, the supernatant A is collected and the precipitated cells are collected at the same time to form a broken cell solution, and the supernatant A and the broken cell solution are simultaneously detected in steps (1) to (3), so that the extracellular and intracellular mycoplasma contents can be detected. For the first time, it is proposed to simultaneously detect the extracellular and intracellular mycoplasma contents of the cell preparation, and the extracellular and intracellular mycoplasma contents of the cell preparation are detected simultaneously, and the extracellular mycoplasma concentration A and the intracellular mycoplasma concentration B are obtained. The ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α. The smaller α is, the less the cell infection in the cell preparation is affected by the extracellular environment of the cell preparation.

[0013] Preferably, in the step (1), in the incubation system in which the cell preparation sample to be tested, α-mannosidase, 6-chloro-3-indole-aD-mannoside, and a buffer solution with a pH of 3.5 to 4.5 are mixed, the concentration of 6-chloro-3-indole-aD-mannoside is 2.5 to 3.5 mg / mL, and the concentration of α-mannosidase is 10 to 15 mg / mL based on protein measurement.

[0014] The above-mentioned cell preparation mycoplasma detection method is tested under the above-mentioned parameter conditions, and the method has better sensitivity and lower detection limit.

[0015] Preferably, the buffer solution with a pH of 3.5 to 4.5 is a 0.08 to 0.15 mol / L citric acid-sodium citrate buffer solution, and the solution after the reaction in step (2) is diluted to 0.8 to 1.5 mL.

[0016] Preferably, the incubation time in step (1) is 20 to 30 minutes.

[0017] Preferably, the solvent of 6-chloro-3-indole-aD-mannoside is a citric acid-sodium citrate buffer solution with a pH of 3.5 to 4.5 and containing 0.7% to 0.8% TritonX-100.

[0018] Preferably, the pH of the buffer solution is 3.9-4.1.

[0019] Preferably, the detection method comprises the following steps:

[0020] (1) Take no more than 150 μL of the quantitative cell preparation sample to be tested and centrifuge, collect the supernatant A and the precipitated cells, add citric acid-sodium citrate buffer with a pH of 3.9 to 4.1 to the supernatant A to make the volume 150 μL to 200 μL, add citric acid-sodium citrate buffer with a pH of 3.9 to 4.1 to resuspend and disrupt the precipitated cells to obtain a disrupted cell solution B, the volume of the supernatant A after the volume is equal to the volume of the disrupted cell solution B, add 150 μL to 200 μL of the supernatant A after the volume is made up, 50 to 100 μL of α-mannosidase with a protein content of 100 to 300 mg / mL, and 50 to 100 μL of 6-chloro-3- Indole-aD-mannoside is incubated in a 0.08-0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9-4.1 at 36.5-37.5° C. for 20-30 minutes to obtain an incubation solution A; 150 μL-200 μL of disrupted cell solution B, 50-100 μL of α-mannosidase with a protein content of 100-300 mg / mL, and 50-100 μL of 25-70 mg / mL 6-chloro-3-indole-aD-mannoside are incubated in a 0.08-0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9-4.1 at 36.5-37.5° C. for 20-30 minutes to obtain an incubation solution B;

[0021] (2) At the end of the incubation, 8 to 15 μL of 100 to 500 mg / mL swainsonine inhibitor was added to the reaction system to terminate the reaction;

[0022] (3) respectively adjusting the volumes of the incubation solution A and the incubation solution B treated in the detection step (2) to 0.8-1.5 mL, and detecting the absorbance signal intensity at 510-513 nm;

[0023] (4) preparing 5 to 8 mycoplasma solutions of different concentrations in the range of 0 to 200 CFU / mL, including a blank solution, and treating the 5 to 8 mycoplasma solutions of different concentrations in accordance with steps (1) to (3) in sequence to obtain a mapping relationship between the mycoplasma solution concentration and the absorbance signal intensity;

[0024] (5) Obtaining the absorbance signal intensity A of the incubation solution A after the volume is fixed and the absorbance signal intensity B of the incubation solution B after the volume is fixed; substituting the absorbance signal intensity A and the absorbance signal intensity B into the mapping relationship obtained in step (4) to obtain the mycoplasma concentration A in the supernatant A and the mycoplasma concentration B in the cell disruption solution B, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α.

[0025] The present invention also provides a cell preparation mycoplasma detection kit, which comprises α-mannosidase, 25-70 mg / mL 6-chloro-3-indole-aD-mannoside, 0.08-0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9-4.1, and 100-500 mg / mL swainsonine inhibitor.

[0026] Preferably, the detection kit further comprises an instruction manual, wherein the instruction manual records at least one of the above-mentioned cell preparation mycoplasma detection methods.

[0027] Preferably, the α-mannosidase is an α-mannosidase with a protein content of 100 to 300 mg / mL, and the solvent of the α-mannosidase is a 0.08 to 0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9 to 4.1.

[0028] Preferably, the solvent of 6-chloro-3-indole-aD-mannoside is a citric acid-sodium citrate buffer solution with a pH of 3.5 to 4.5 and containing 0.7% to 0.8% TritonX-100.

[0029] The beneficial effects of the present invention are as follows: the present invention provides a method for detecting mycoplasma in a cell preparation and a kit thereof. In the method for detecting mycoplasma in a cell preparation of the present invention, mycoplasma has an inhibitory effect on α-mannosidase, and after α-mannosidase hydrolyzes the chromogenic substrate 6-chloro-3-indole-aD-mannoside, the absorbance signal at 505-515nm changes, and by constructing a mapping relationship between the mycoplasma content and the absorbance signal, mycoplasma detection in a cell preparation can be achieved. The method for detecting mycoplasma in a cell preparation of the present invention can detect the extracellular and intracellular mycoplasma content, and simultaneously detect the extracellular and intracellular mycoplasma content of the cell preparation, and for the first time proposes the simultaneous detection of the extracellular and intracellular mycoplasma content of the cell preparation, and obtains the extracellular mycoplasma concentration A and the intracellular mycoplasma concentration B, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α, and the smaller α is, the less the cell infection in the cell preparation is affected by the extracellular environment of the cell preparation. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 This is a diagram showing the experimental results of the mycoplasma detection method for cell preparations of the present invention.

[0031] Figure 2 This is a diagram showing the experimental results of the mycoplasma detection method for cell preparations of the present invention. DETAILED DESCRIPTION

[0032] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0033] Example 1

[0034] A method for detecting mycoplasma in a cell preparation as an embodiment of the present invention comprises the following steps:

[0035] (1) Take no more than 150 μL of the quantitative cell preparation sample to be tested and centrifuge, collect the supernatant A and the precipitated cells, add 0.1 mol / L citric acid-sodium citrate buffer with a pH of 4.0 to the supernatant A to make the volume 150 μL to 200 μL, add 0.1 mol / L citric acid-sodium citrate buffer with a pH of 4.0 to the precipitated cells to resuspend and disrupt them to obtain a disrupted cell solution B, the volume of the supernatant A after the volume is equal to the volume of the disrupted cell solution B, add 150 μL to 200 μL of the supernatant A after the volume is fixed, 50 to 100 μL of α-mannosidase with a protein content of 100 to 300 mg / mL, and 50 to 100 μL of 6-chloro-3- Indole-aD-mannoside is incubated in a 0.1 mol / L citric acid-sodium citrate buffer solution with a pH of 4.0 and a concentration of 0.08-0.15 mol / L at 36.5-37.5° C. for 20-30 minutes to obtain an incubation solution A; 150 μL-200 μL of disrupted cell solution B, 50-100 μL of α-mannosidase with a protein concentration of 100-300 mg / mL, and 50-100 μL of 25-70 mg / mL of 6-chloro-3-indole-aD-mannoside are incubated in a 0.1 mol / L citric acid-sodium citrate buffer solution with a pH of 4.0 and a concentration of 0.08-0.15 mol / L at 36.5-37.5° C. for 20-30 minutes to obtain an incubation solution B;

[0036] (2) At the end of the incubation, 8 to 15 μL of 100 to 500 mg / mL swainsonine inhibitor was added to the reaction system to terminate the reaction;

[0037] (3) respectively adjusting the volumes of the incubation solution A and the incubation solution B treated in the detection step (2) to 0.8-1.5 mL, and detecting the absorbance signal intensity at 510-513 nm;

[0038] (4) preparing 5 to 8 mycoplasma solutions of different concentrations in the range of 0 to 200 CFU / mL, including a blank solution, and treating the 5 to 8 mycoplasma solutions of different concentrations in accordance with steps (1) to (3) in sequence to obtain a mapping relationship between the mycoplasma solution concentration and the absorbance signal intensity;

[0039] (5) Obtaining the absorbance signal intensity A of the incubation solution A after the volume is fixed and the absorbance signal intensity B of the incubation solution B after the volume is fixed; substituting the absorbance signal intensity A and the absorbance signal intensity B into the mapping relationship obtained in step (4) to obtain the mycoplasma concentration A in the supernatant A and the mycoplasma concentration B in the cell disruption solution B, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α.

[0040] Experimental methods

[0041] 1. Optimization of detection parameters

[0042] 1. Experimental Materials

[0043] α-Mannosidase was α-D-mannosidase (canavalin A source) purchased from SIGMA; 6-chloro-3-indole-aD-mannoside and swainsonine were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. Mycoplasma was Mycoplasma hominis (ATCC15488) purchased from Shanghai Hanni Biotechnology Co., Ltd.; Oxoid Mycoplasma Agar CM0401B and Mycoplasma Additive SR0060C were purchased from Shunyou (Shanghai) Biotechnology Co., Ltd.

[0044] (II) Mycoplasma culture

[0045] Take 80mL of mycoplasma additive SR0060C and 20mL of sterile distilled water, mix and dissolve, add 1mL of mycoplasma agar base, sterilize at 121℃ for 15 minutes, and add 2mL of dissolved mycoplasma additive SR0060C. This is the mycoplasma culture medium.

[0046] The standard strain of Mycoplasma hominis was reconstituted with sterile water and the lyophilized powder was inoculated into the culture medium and incubated at 37°C for 18 to 24 hours until the concentration of mycoplasma reached 10 6 Stop the culture at CCU / mL and store at 4℃ for future use.

[0047] (III) Optimization of incubation time

[0048] 10 6 Mycoplasma diluted to 10 CCU / mL 4 CCU / mL, and then take the concentration of 10 4CCU / mL was added to 0.1mol / L citric acid-sodium citrate buffer at pH 4.0 to prepare 150μL of mycoplasma solution with a concentration of 100CCU / mL, 100μL of α-mannosidase with a protein content of 120mg / mL, and 100μL of 6-chloro-3-indole-aD-mannoside with a concentration of 30mg / mL. The incubation solution was obtained by incubating at 37°C for 10 minutes, 15 minutes, 20 minutes, 30 minutes, 45 minutes, and 60 minutes, respectively. 10μL of 300mg / mL swainsonine was added, and the volume was adjusted to 1mL to detect the absorbance signal intensity at 512nm. The experimental results are shown in Figure 1 shown.

[0049] Depend on Figure 1 It can be seen that when the incubation time is 20 minutes to 30 minutes, there is a higher response and the detection time is shorter.

[0050] (IV) Mapping relationship between mycoplasma solution concentration and absorbance signal intensity

[0051] Take the concentration of 10 4 CCU / mL was added to 0.1mol / L citric acid-sodium citrate buffer at pH 4.0 to prepare mycoplasma concentrations of 2CCU / mL, 5CCU / mL, 10CCU / mL, 20CCU / mL, 50CCU / mL, 100CCU / mL, and 200CCU / mL. 150μL of mycoplasma solution of different concentrations, 100μL of α-mannosidase with a protein content of 120mg / mL, and 100μL of 6-chloro-3-indole-aD-mannoside with a concentration of 30mg / mL were taken and incubated at 37°C for 20 minutes to obtain incubation solution, 10μL of 300mg / mL swainsonine was added, and the volume was fixed to 1mL to detect the absorbance signal intensity at 512nm. The experimental results are as follows Figure 2 shown.

[0052] Depend on Figure 2 It can be seen that there is a good linear relationship in the range of 2CCU / mL to 200CCU / mL. 2 The value of Adg-R in the range of 2CCU / mL to 100CCU / mL was 0.9972, mainly because the deviation from linearity was large at 200CCU / mL. 2 The detection limit is 0.999.

[0053] (V) Cell culture and detection

[0054] 1. Experimental materials:

[0055] Human umbilical cord mesenchymal stem cells (HUCMSC) were purchased from Sciencell, USA.

[0056] (1) Cell recovery: Take out the cryopreserved tube of umbilical cord mesenchymal stem cells stored in liquid nitrogen, thaw it in a 37°C constant temperature water bath, transfer it into a 15 ml centrifuge tube containing 5 ml PBS with a pipette, centrifuge at 1000 rpm for 5 min, discard the supernatant, add 8 ml of MSC-specific culture medium, inoculate it into a 10 cm culture dish, and transfer it to a 37°C, 5% CO 2 The cells were cultured in a cell culture incubator, and the medium was changed every 48 hours;

[0057] (2) Cell passaging: When the cells in the culture dish grow to 90% confluence, they are expanded and passaged. The cells are rinsed with PBS to remove floating cells and debris, and digested with 0.25% trypsin. Observe under a microscope. When the intercellular gap increases and the cells shrink and become round, use a medium twice the volume of trypsin to terminate the digestion. Collect the suspended cells and transfer them to a 15 ml centrifuge tube. Centrifuge for 5 min, discard the supernatant, resuspend the cells in the medium, and pass the culture at a ratio of 1:4.

[0058] (3) The cell concentration of mesenchymal stem cells passaged to the fourth generation was adjusted to 5×10 6 / ml.

[0059] 2. Inoculate the single cell suspension into a culture flask containing 5 mL of complete cell culture medium in proportion to make the cell concentration reach 10 4 / ml, add 0.5mL 20CCU / mL mycoplasma, and transfer to 37℃, 5% CO 2 The cells were cultured in a cell culture incubator for 6 hours as the experimental group.

[0060] A control group without 0.5 mL of 20 CCU / mL of mycoplasma was set up.

[0061] After 6 hours of culture, shake well, take 150 μL as the sample to be tested, centrifuge 150 μL of the sample cell solution, collect supernatant A and precipitated cells, add 0.1 mol / L citric acid-sodium citrate buffer with pH 4.0 to the supernatant A to make the volume 150 μL, add 150 μL 0.1 mol / L citric acid-sodium citrate buffer with pH 4.0 to resuspend and break the precipitated cells, and break them with an ultrasonic cell disruptor under ice bath protection, set the parameters to 100 W, and run 3s, stop 3s, and perform 20 times to obtain the broken cell solution B. The volume of the supernatant A after constant volume is equal to the volume of the broken cell solution B. 100μL of α-mannosidase with a protein content of 120mg / mL and 100μL of 6-chloro-3-indole-aD-mannoside with a concentration of 30mg / mL are incubated at 37°C for 20 minutes to obtain the incubation solution, 10μL of 300mg / mL swainsonine is added, and the volume is constant to 1mL to detect the absorbance signal intensity at 512nm. Substitute into the above linear relationship to calculate the intracellular and extracellular mycoplasma concentrations. The experimental results are shown in Table 1.

[0062] experiment Mycoplasma concentration CCU / mL Control group supernatant Not detected Control group broken cell fluid Not detected Experimental group supernatant 26.4 Experimental group cell suspension 287.6

[0063] As can be seen from Table 1, the method for detecting mycoplasma in a cell preparation of the present invention proposes to simultaneously detect the extracellular and intracellular mycoplasma contents of a cell preparation, and simultaneously detects the extracellular and intracellular mycoplasma contents of a cell preparation, and obtains the mycoplasma concentration A in the supernatant, i.e., the extracellular mycoplasma concentration, and the mycoplasma concentration B in the cell disrupted liquid, i.e., the intracellular mycoplasma concentration. The ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α, and the smaller α is, the less the cell infection in the cell preparation is affected by the extracellular environment of the cell preparation.

[0064] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A method for detecting mycoplasma in cell preparations, characterized in that: The detection method comprises the following steps: (1) incubating the quantitative cell preparation sample to be tested with quantitative α-mannosidase and quantitative 6-chloro-3-indole-aD-mannoside in a buffer solution with a pH of 3.5 to 4.5 at 36 to 38° C. for 15 to 60 minutes; (2) at the end of the incubation, a quantitative swainsonine inhibitor was added to the reaction system to terminate the reaction; (3) detecting the absorbance signal intensity of the liquid treated in step (2) at 505 to 515 nm; (4) preparing 5 to 8 mycoplasma solutions of different concentrations in the range of 0 to 200 CFU / mL, including a blank solution, and treating the 5 to 8 mycoplasma solutions of different concentrations in accordance with steps (1) to (3) in sequence to obtain a mapping relationship between the mycoplasma solution concentration and the absorbance signal intensity; (5) Substituting the absorbance signal intensity of the cell preparation sample to be tested into the mapping relationship obtained in step (4) to calculate the mycoplasma concentration in the cell preparation sample to be tested.

2. The method for detecting mycoplasma in cell preparations according to claim 1, characterized in that: In the step (1), the quantitative cell preparation sample to be tested is centrifuged to collect the supernatant A and the precipitated cells; the precipitated cells are added to a quantitative buffer solution with a pH of 3.5 to 4.5 for suspension and mechanical disruption to obtain a cell disruption solution B; the supernatant A and the cell disruption solution B are respectively subjected to the treatment and detection of steps (1) to (3) to obtain an absorbance signal intensity A of the supernatant A and an absorbance signal intensity B of the cell disruption solution B; the absorbance signal intensity A and the absorbance signal intensity B are substituted into the mapping relationship obtained in step (4) to obtain a mycoplasma concentration A in the supernatant A and a mycoplasma concentration B in the cell disruption solution B, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α.

3. The method for detecting mycoplasma in cell preparations according to claim 1, characterized in that: In the step (1), in the incubation system in which the cell preparation sample to be tested, α-mannosidase, 6-chloro-3-indole-aD-mannoside, and a buffer solution with a pH of 3.5 to 4.5 are mixed, the concentration of 6-chloro-3-indole-aD-mannoside is 2.5 to 3.5 mg / mL, and the concentration of α-mannosidase is 10 to 15 mg / mL based on protein measurement.

4. The method for detecting mycoplasma in cell preparations according to claim 1, characterized in that: The buffer solution with a pH of 3.5 to 4.5 is a 0.08 to 0.15 mol / L citric acid-sodium citrate buffer solution, and the solution after the reaction in step (2) is diluted to 0.8 to 1.5 mL.

5. The method for detecting mycoplasma in cell preparations according to claim 1, characterized in that: The incubation time in step (1) is 20 to 30 minutes.

6. The method for detecting mycoplasma in cell preparations according to claim 1, characterized in that: The solvent of 6-chloro-3-indole-aD-mannoside is a citric acid-sodium citrate buffer solution with a pH of 3.5 to 4.5 and containing 0.7% to 0.8% TritonX-100.

7. The method for detecting mycoplasma in cell preparations according to claim 1, characterized in that: The pH of the buffer solution is 3.9-4.

1.

8. The method for detecting mycoplasma in cell preparations according to claim 1, characterized in that: The detection method comprises the following steps: (1) Take no more than 150 μL of the quantitative cell preparation sample to be tested and centrifuge, collect the supernatant A and the precipitated cells, add citric acid-sodium citrate buffer with a pH of 3.9 to 4.1 to the supernatant A to make the volume 150 μL to 200 μL, add citric acid-sodium citrate buffer with a pH of 3.9 to 4.1 to resuspend and disrupt the precipitated cells to obtain a disrupted cell solution B, the volume of the supernatant A after the volume is equal to the volume of the disrupted cell solution B, add 150 μL to 200 μL of the supernatant A after the volume is made up, 50 to 100 μL of α-mannosidase with a protein content of 100 to 300 mg / mL, and 50 to 100 μL of 6-chloro-3- Indole-aD-mannoside is incubated in a 0.08-0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9-4.1 at 36.5-37.5° C. for 20-30 minutes to obtain an incubation solution A; 150 μL-200 μL of disrupted cell solution B, 50-100 μL of α-mannosidase with a protein content of 100-300 mg / mL, and 50-100 μL of 25-70 mg / mL 6-chloro-3-indole-aD-mannoside are incubated in a 0.08-0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9-4.1 at 36.5-37.5° C. for 20-30 minutes to obtain an incubation solution B; (2) At the end of the incubation, 8 to 15 μL of 100 to 500 mg / mL swainsonine inhibitor was added to the reaction system to terminate the reaction; (3) respectively adjusting the volumes of the incubation solution A and the incubation solution B treated in the detection step (2) to 0.8-1.5 mL, and detecting the absorbance signal intensity at 510-513 nm; (4) preparing 5 to 8 mycoplasma solutions of different concentrations in the range of 0 to 200 CFU / mL, including a blank solution, and treating the 5 to 8 mycoplasma solutions of different concentrations in accordance with steps (1) to (3) in sequence to obtain a mapping relationship between the mycoplasma solution concentration and the absorbance signal intensity; (5) Obtaining the absorbance signal intensity A of the incubation solution A after the volume is fixed and the absorbance signal intensity B of the incubation solution B after the volume is fixed; substituting the absorbance signal intensity A and the absorbance signal intensity B into the mapping relationship obtained in step (4) to obtain the mycoplasma concentration A in the supernatant A and the mycoplasma concentration B in the cell disruption solution B, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is recorded as the environmental impact coefficient α.

9. A cell preparation mycoplasma detection kit, characterized in that: The detection kit contains α-mannosidase, 25-70 mg / mL 6-chloro-3-indole-aD-mannoside, 0.08-0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9-4.1, and 100-500 mg / mL swainsonine inhibitor.

10. A cell preparation mycoplasma detection kit, characterized in that: The detection kit further comprises an instruction manual, which records at least one of the cell preparation mycoplasma detection methods according to claims 1 to 8; the α-mannosidase is an α-mannosidase with a protein content of 100 to 300 mg / mL, the solvent of the α-mannosidase is a 0.08 to 0.15 mol / L citric acid-sodium citrate buffer solution with a pH of 3.9 to 4.1, and the solvent of 6-chloro-3-indole-aD-mannoside is a citric acid-sodium citrate buffer with a pH of 3.5 to 4.5 containing 0.7% to 0.8% TritonX-100.

Citation Information

Patent Citations

  • Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated n-glycans and methods of facilitating mammalian cellular uptake of glycoproteins

    CA2812870A1

  • Method for detecting bacterial pollution in cell preparation

    CN118932012A

Cited By

  • Cell preparation mycoplasma detection method and kit thereof

    CN120945085A